Breaking News Instant updates and real-time market news.

MBIO

Mustang Bio

$4.65

0.61 (15.10%)

08:05
08/22/19
08/22
08:05
08/22/19
08:05

Mustang Bio granted RMAT designation for MB-107 for XSCID

Mustang Bio and St. Jude Children's Research Hospital have announced that MB-107, a lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease, has been granted the Regenerative Medicine Advanced Therapy designation by the U.S. Food and Drug Administration. Mustang and St. Jude, the nation's leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases, established a partnership to continue development of the lentiviral gene therapy in August 2018. Under the terms of the RMAT designation, the FDA will help facilitate the program's expedited development and review and provide guidance on generating the evidence needed to support the approval of MB-107 for XSCID. RMAT designation was granted to MB-107 based on positive Phase 1/2 clinical data for infants with XSCID under the age of 2, which were published in the New England Journal of Medicine in April 2019.

  • 04

    Sep

MBIO Mustang Bio
$4.65

0.61 (15.10%)

04/18/19
HCWC
04/18/19
NO CHANGE
HCWC
H.C. Wainwright says Fortress business model validated by Mustang data
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $11 price target on Fortress Biotech (FBIO), noting that Mustang Bio (MBIO), a Fortress Biotech Company, published positive data related to its Phase 1/2 trial in children with XSCID, also known as bubble boy disease, delivering "compelling safety and efficacy." Pantginis sees Fortress continuing "to participate in the shares' appreciation showing continued validation of its business model."
06/20/19
CANT
06/20/19
INITIATION
Target $7
CANT
Overweight
Mustang Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros initiated Mustang Bio with an Overweight and $7 price target.
06/21/19
CANT
06/21/19
INITIATION
Target $7
CANT
Overweight
Cantor starts Mustang Bio with Overweight rating, $7 price target
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Mustang Bio with an Overweight rating and $7 price target. The company's pipeline centers on various gene and cell therapies are partnered with leading academic foundations, Piros tells investors in a research note. The analyst believes this approach of in-licensing these assets "may lift initial risks for future clinical development."
08/13/19
HCWC
08/13/19
INITIATION
Target $7
HCWC
Buy
Mustang Bio initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Mustang Bio with a Buy rating and $7 price target. The analyst believes Mustang has a high probability of clinical success and that its "strong" academic partnerships may lead to "high quality" clinical data and provide additional funding while decreasing potential shareholder dilution. These factors highlight a "valuation disconnect for investors currently looking for compelling opportunities in an overcrowded biotech arena," Pantginis tells investors in a research note.

TODAY'S FREE FLY STORIES

XLRN

Acceleron

$44.67

0.75 (1.71%)

06:43
09/17/19
09/17
06:43
09/17/19
06:43
Recommendations
Acceleron analyst commentary  »

Acceleron should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 04

    Dec

  • 04

    Apr

CBMG

Cellular Biomedicine

$14.75

-0.16 (-1.07%)

06:43
09/17/19
09/17
06:43
09/17/19
06:43
Initiation
Cellular Biomedicine initiated  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGOV

NIC Inc.

$21.79

0.05 (0.23%)

06:40
09/17/19
09/17
06:40
09/17/19
06:40
Downgrade
NIC Inc. rating change  »

NIC Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SPLK

Splunk

$114.87

1.19 (1.05%)

06:39
09/17/19
09/17
06:39
09/17/19
06:39
Upgrade
JPMorgan upgrades Splunk to Overweight after 19% selloff since late July »

JPMorgan analyst Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

OLN

Olin

$19.27

0.46 (2.45%)

06:38
09/17/19
09/17
06:38
09/17/19
06:38
Conference/Events
Olin management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

CBMG

Cellular Biomedicine

$14.75

-0.16 (-1.07%)

06:38
09/17/19
09/17
06:38
09/17/19
06:38
Initiation
Cellular Biomedicine initiated  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXNX

Axonics

$30.13

-0.77 (-2.49%)

06:37
09/17/19
09/17
06:37
09/17/19
06:37
Initiation
Axonics initiated  »

Axonics initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXGBY

Hexagon AB

$0.00

(0.00%)

06:36
09/17/19
09/17
06:36
09/17/19
06:36
Conference/Events
Hexagon AB management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

APOG

Apogee Enterprises

$41.18

-0.38 (-0.91%)

06:34
09/17/19
09/17
06:34
09/17/19
06:34
Earnings
Apogee Enterprises reaffirms FY20 EPS view $3.00-$3.20, consensus $3.05 »

Reaffirms FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

MDGL

Madrigal Pharmaceuticals

$99.50

4.89 (5.17%)

06:34
09/17/19
09/17
06:34
09/17/19
06:34
Recommendations
Madrigal Pharmaceuticals analyst commentary  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$0.00

(0.00%)

, UBER

Uber

$34.42

1.18 (3.55%)

06:32
09/17/19
09/17
06:32
09/17/19
06:32
Periodicals
SoftBank backers consider slashing committments to Vision Fund, Bloomberg says »

The biggest backers of…

SFTBF

SoftBank

$0.00

(0.00%)

UBER

Uber

$34.42

1.18 (3.55%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSI

Stage Stores

$0.85

0.0298 (3.63%)

06:32
09/17/19
09/17
06:32
09/17/19
06:32
Hot Stocks
Stage Stores announces plans to convert substantially all stores to off-price »

Stage Stores announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APOG

Apogee Enterprises

$41.18

-0.38 (-0.91%)

06:31
09/17/19
09/17
06:31
09/17/19
06:31
Earnings
Apogee Enterprises reports Q2 EPS 72, consensus 64c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

IAC

IAC

$229.23

1.71 (0.75%)

06:30
09/17/19
09/17
06:30
09/17/19
06:30
Initiation
IAC initiated  »

IAC initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

AMRN

Amarin

$17.26

0.55 (3.29%)

, MDCO

The Medicines Co.

$48.74

0.99 (2.07%)

06:29
09/17/19
09/17
06:29
09/17/19
06:29
Recommendations
Citi puts Amarin and Sarepta on top five SMid cap biotech pick list »

Citi analyst Joel Beatty…

AMRN

Amarin

$17.26

0.55 (3.29%)

MDCO

The Medicines Co.

$48.74

0.99 (2.07%)

NERV

Minerva

$8.12

0.12 (1.50%)

SRPT

Sarepta

$87.02

1.01 (1.17%)

ELOX

Eloxx Pharmaceuticals

$6.45

0.1 (1.57%)

NGM

NGM Biopharmaceuticals

$15.85

-0.15 (-0.94%)

PTCT

PTC Therapeutics

$42.99

0.16 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MRVL

Marvell

$25.39

-0.46 (-1.78%)

06:28
09/17/19
09/17
06:28
09/17/19
06:28
Hot Stocks
SEC says Marvell Technology to pay $5.5M to settle disclosure-related charges »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANGI

Angi Homeservices

$7.91

-0.075 (-0.94%)

, GOOG

Alphabet

$1,231.36

-8.24 (-0.66%)

06:28
09/17/19
09/17
06:28
09/17/19
06:28
Initiation
Angi Homeservices, Alphabet, Alphabet Class A initiated  »

Angi Homeservices…

ANGI

Angi Homeservices

$7.91

-0.075 (-0.94%)

GOOG

Alphabet

$1,231.36

-8.24 (-0.66%)

GOOGL

Alphabet Class A

$1,231.45

-8.68 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

MTCH

Match Group

$76.70

1.74 (2.32%)

06:26
09/17/19
09/17
06:26
09/17/19
06:26
Initiation
Match Group initiated  »

Match Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPL

LG Display

$6.42

-0.01 (-0.16%)

, AAPL

Apple

$219.88

1.17 (0.53%)

06:26
09/17/19
09/17
06:26
09/17/19
06:26
Periodicals
LG Display plans voluntary redundancy program, Reuters reports »

LG Display (LPL) plans to…

LPL

LG Display

$6.42

-0.01 (-0.16%)

AAPL

Apple

$219.88

1.17 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$17.11

-0.11 (-0.64%)

06:24
09/17/19
09/17
06:24
09/17/19
06:24
Hot Stocks
Barrick Gold says Acacia Mining scheme becomes effective »

On July 19, the Boards of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXRP

Lexaria Bioscience

$0.00

(0.00%)

06:22
09/17/19
09/17
06:22
09/17/19
06:22
Hot Stocks
Lexaria Bioscience says TurboCBD capsule study results published »

Lexaria Bioscience…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFNNY

Infineon

$0.00

(0.00%)

, SNPS

Synopsys

$133.17

-1.45 (-1.08%)

06:20
09/17/19
09/17
06:20
09/17/19
06:20
Hot Stocks
Infineon enters collaboration with Synopsys »

Infineon Technologies AG…

IFNNY

Infineon

$0.00

(0.00%)

SNPS

Synopsys

$133.17

-1.45 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

EADSY

Airbus

$0.00

(0.00%)

06:19
09/17/19
09/17
06:19
09/17/19
06:19
Periodicals
Airbus doesn't see major 2019 impact from tariffs, Reuters reports »

Possible U.S. tariffs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVER

EverQuote

$24.73

2.33 (10.40%)

06:18
09/17/19
09/17
06:18
09/17/19
06:18
Downgrade
EverQuote rating change  »

EverQuote downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$49.04

-0.45 (-0.91%)

06:15
09/17/19
09/17
06:15
09/17/19
06:15
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.